Etanercept (Enbrel®) in patients with rheumatoid arthritis with recent onset versus established disease: Improvement in disability

Journal of Rheumatology

Volumn 31, Issue 8, 2004, Pages 1532-1537

  Baumgartner, Scott W ^a   Fleischmann, Roy M ^b   Moreland, Larry W ^c   Schiff, Michael H ^d   Markenson, Joseph ^e   Whitmore, James B ^f  

^a Physician's Clinic of Spokane   (United States)

^b RADIANT RESEARCH   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Denver Arthritis Clinic   (United States)

^e Hospital for Special Surgery   (United States)

^f AMGEN INC   (United States)

Author keywords

Disease modifying antirheumatic drugs; Etanercept; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENERAL CONDITION IMPROVEMENT; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TIME; TREATMENT FAILURE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HEALTH STATUS; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; RETREATMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 3442882494     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000;43:2751-61.
2. Pincus T, Callahan LF, Fuchs HA, Larsen A, Kaye J. Quantitative analysis of hand radiographs in rheumatoid arthritis: time course of radiographic changes, relation to joint examination measures, and comparison of different scoring methods. J Rheumatol 1995;22:1983-9.
3. Stenger AA, Van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157-63.
4. Rich E, Moreland LW, Alarcon GS. Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug [comment]. J Rheumatol 1999;26:259-61.
5. Gordon P, West J, Jones H, Gibson T. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. J Rheumatol 2001;28:2409-15.
6. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
7. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
8. Moreland LW, Cohen SB, Baumgartner SW, et al, Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
9. Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol 1993;20:561-5.
10. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
11. Wolfe F, Kleinheksel SM, Cathey MA, Hawley DJ, Spitz PW, Fries JF. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988;15:1480-8.
12. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
13. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
14. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986;13:841-5.
15. Young A, van der Heijde DM. Can we predict aggressive disease? Baillieres Clin Rheumatol 1997;11:27-48,
16. Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology Oxford 2000;39:603-11.
17. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009-17.
18. Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology Oxford 2000;39:122-32.
19. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
20. Lipsky PE, Van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
21. Strand V. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
22. Emery PBF, Breedfeld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology Oxford 2000;39:655-65.
23. Ory PA. Interpreting radiographic data in rheumatoid arthritis. Ann Rheum Dis 2003;62:597-604.
24. Lovinger SP. Use of biologics for rheumatoid arthritis tempered by concerns over safety, cost. JAMA 2003;289:3229-30.